Retatrutide (Compounded)

Description

Retatrutide is a novel peptide designed as a GLP-1 / GIP / glucagon receptor triple agonist, currently under investigation for its unmatched weight loss potential. Early clinical trials have shown it to significantly outperform both semaglutide and tirzepatide in reducing body fat and improving metabolic markers.

Unlike previous generation compounds, Retatrutide activates three key pathways involved in appetite control, fat burning, and glucose regulation — making it one of the most promising candidates in obesity and metabolic research.

✅ Triple receptor agonist: GLP-1 + GIP + Glucagon
✅ Strong appetite suppression
✅ Enhanced fat oxidation and thermogenesis
✅ May improve glucose control and insulin sensitivity
✅ Research suggests superior weight loss effects
✅ No prescription required

Product Specs:
🔹 Content: 15mg lyophilized Retatrutide peptide
🔹 Purity: 99%
🔹 Form: Freeze-dried powder for reconstitution
🔹 Packaging: Sterile, resealable research vial

Administration:
Supplied as a 15mg lyophilized peptide. For research purposes, reconstitute with 3mL of bacteriostatic water (sold separately).
In early research, dosages typically begin at 2mg per week, gradually increasing up to 8–12mg per week depending on tolerance and protocol length. Subcutaneous administration is used once per week.
Reconstituted solution should be refrigerated. Store dry powder in a cool, dry place away from light and moisture.

📦 Discreet, Fast Shipping Across Australia
Orders are processed within 24 hours. Tracked shipping available.